Samantha Dewundara, MD
Ophthalmology · Norfolk, VANPI 1659689693
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,419 of the $18,797 with a category attached, or 76.7%. 22 manufacturers reported payments, led by Tarsus Pharmaceuticals, Inc. at 58.3% of the total. Reporting peaked in 2024 at $11,676 and has fallen 91.3% since, to $1,014 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $102.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tarsus Pharmaceuticals, Inc.$11K
- Aerie Pharmaceuticals, Inc.$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Mallinckrodt Hospital Products Inc.$425
- Sun Pharmaceutical Industries Inc.$373
- plus $2K from 16 others
What the payments were for
- Consulting fees$14,41977%
- Food & beverage$4,17822%
- Education$2001%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tarsus Pharmaceuticals, Inc. | 15 | $10,951 |
| Aerie Pharmaceuticals, Inc. | 21 | $2,963 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $1,411 |
| AbbVie(2 entities) | 53 | $1,160 |
| Mallinckrodt Hospital Products Inc. | 12 | $425 |
| Sun Pharmaceutical Industries Inc. | 15 | $373 |
| Bausch & Lomb Americas Inc. | 11 | $207 |
| Novartis | 9 | $200 |
| Dompe US, Inc. | 6 | $182 |
| Regeneron Healthcare Solutions, Inc. | 6 | $162 |
| Alcon | 7 | $140 |
| NEW World Medical,inc. | 1 | $103 |
| Amgen(2 entities) | 4 | $82 |
| Sight Sciences, Inc. | 1 | $79 |
| Thea Pharma Inc. | 3 | $66 |
| Biotissue Holdings Inc. | 3 | $65 |
| Kala Pharmaceuticals, Inc. | 4 | $65 |
| Oyster Point Pharma, Inc. | 2 | $52 |
| Harrow Eye, LLC | 2 | $40 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Glaukos Corporation | 1 | $24 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,797 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $88,444 |
| RocklatanNetarsudil Mesylat/Latanoprost | 102 | $68,455 |
| RestasisCyclosporine | 38 | $53,912 |
| LumiganBimatoprost | 101 | $52,672 |
| RhopressaNetarsudil Mesylate | 60 | $42,253 |
| VyzultaLatanoprostene Bunod | 43 | $36,248 |
| CombiganBrimonidine Tartrate/Timolol | 45 | $19,367 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 63 | $17,028 |
| Cyclosporine | 22 | $14,706 |
| Latanoprost | 893 | $9,964 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $9,653 |
| Brinzolamide | 22 | $7,729 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 332 | $7,185 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 29 | $5,877 |
| Brimonidine Tartrate | 202 | $5,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,160 | $125,951184 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $2,963 | $110,708162 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $207 | $36,24843 claims |
| AlconSimbrinza | $140 | $9,65330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Thomas JolyNorfolk$95K
- Stephen ScoperNorfolk$88K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
- Ethnie JonesRichmond$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.